Diffuse large B-cell lymphoma trials in Poland

In Poland 15 Also abroad 346

15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Gliwice, Katowice, Lublin, Olsztyn, Slupsk, Wroclaw
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Poznan, Skorzewo, Wałbrzych, Warsaw, Wroclaw
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Cracow, Katowice, Skorzewo, Warsaw
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Cracow, Katowice, Slupsk, Walbrzych, Warsaw
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 2Taking people
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Where
Cracow, Gdansk, Katowice, Nowy Sacz, Skorzewo, Walbrzych, Warsaw
Age
18 years and over
People
594 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Cracow, Katowice, Skorzewo, Warsaw
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Bydgoszcz, Cracow, Koszalin, Warsaw
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Gdansk, Poznan, Warsaw
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Krakow, Lodz, Lublin, Skorzewo
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Katowice, Krakow, Lublin, Skórzewo, Warsaw, Wroclaw
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Wroclaw
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
Phase 1Taking people
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
Where
Wroclaw
Age
18 years and over
People
18
Run by
Wroclaw Medical University
See details and how to join2024-519318-30-00 · EU 2024-519318-30-00
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Gdansk, Lodz, Warsaw
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 2Taking people
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Gdynia, Legnica, Olsztyn, Skórzewo, Warsaw
Age
18 years and over
People
102 worldwide
Run by
ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Gdansk, Gliwice, Krakow, Wroclaw
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394